Tariff Impact Analysis for Novartis

Analysis

Novartis has proactively mitigated the impact of U.S. tariffs introduced in April 2025, commonly referred to as "Liberation Day" or reciprocal tariffs. The company's strategy centered on a major reshoring initiative and a regulatory agreement with the U.S. government. Novartis committed to a $23 billion investment over several years to expand its U.S. manufacturing footprint, with the goal of producing 100% of its key U.S. products end-to-end within the country. This reshoring effort, which includes the construction of nine new facilities in states like North Carolina, Florida, and Texas, is intended to insulate the company from future import duties by localizing the supply chain for the U.S. market.

On December 19, 2025, Novartis reached a voluntary "Most Favored Nation" (MFN) agreement with the U.S. administration to lower prices for certain innovative medicines to match those in other high-income countries. In exchange for this pricing commitment and its significant manufacturing investments, Novartis received a three-year exemption from the reciprocal tariffs. Management has characterized this deal as a de-risking event that provides commercial certainty and essentially eliminates the direct cost impact of new tariffs through the exemption period.

The financial impact of the tariffs in 2025 was described as manageable and was fully accounted for in the company's prior guidance. Novartis reported a strong performance for FY2025, with sales increasing 8% to $54.5 billion and reaching its 40% core margin target two years ahead of schedule. While some supply chain adjustments, such as increased inventory levels and expanded warehousing in the U.S., were made early in the year to blunt the initial tariff risk, these did not prevent the company from achieving record core operating income and free cash flow.

Looking ahead to 2026, Novartis expects low single-digit sales growth, a slowdown from 2025 levels. This guidance fully absorbs the expected revenue headwinds from the MFN pricing agreement. However, the primary driver of this lower growth is not the tariff policy but rather the "largest patent expiry in Novartis history," which is expected to create a $4.0 billion revenue gap in 2026 due to generic entries for Entresto, Promacta, and Tasigna. Management noted that the MFN pricing impact is not considered material to the 2026 guidance and is already factored into the company's long-term 5% to 6% sales CAGR through 2030.

Data

Summary of Tariff Mitigation and Strategic Impacts

Source: Transcript FY-2025, Meet the Management Presentation 2025, Novartis Press Release (Dec 19, 2025)

Sources

Our MFN agreement includes provisions that exclude us from tariffs for three years, as long as we keep investing. So tariffs are mitigated. On the MFN, it took us months, but we came to a place where I think it’s a pretty reasonable approach that allows us to maintain our one-year and five-year guidance.

That puts us in a very good place to have supply coming from factories in the US for the US, which essentially eliminates the impact of any new tariffs.

Our guidance fully accounts for any potential tariffs that we've modeled or scenarios that we expect in this year and in the medium-term guidance. We think it is manageable and not something that we need to highlight with respect to our financial outlook.